International Journal of Advances in Medicine | May 2022 | Vol 9 | Issue 5 Page 583 International Journal of Advances in Medicine Giri R et al. Int J Adv Med. 2022 May;9(5):583-586 http://www.ijmedicine.com pISSN 2349-3925 | eISSN 2349-3933 Original Research Article A study of non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus and its correlation with cardiovascular risk Richa Giri, Vinit Kumar*, Vinay Kumar, Saurabh Agarwal INTRODUCTION NAFLD encompasses a variety of disorders of lipid metabolism ranging from NAFL (non-alcoholic fatty liver), NASH (non-alcoholic steatohepatitis) to cirrhosis and rarely HCC in very severe form. It is defined as hepatic steatosis in >5% of hepatocytes according to histological analysis or by proton density fat fraction or >5.6% as assessed by proton magnetic resonance spectroscopy (MRS) or quantitative fat/water selective magnetic resonance imaging (MRI) with no secondary cause for steatosis. 1 NAFLD is the most common cause of abnormal liver function test among western countries 2 and is commonly associated with components of metabolic syndrome supporting the idea of it being a hepatic manifestation of the syndrome. As obesity and insulin resistance has been strongly associated with NAFLD, the prevalence of NAFLD is higher in T2DM ABSTRACT Background: NAFLD (non-alcoholic fatty liver disease) encompasses a variety of disorders of lipid metabolism ranging from NAFL, NASH to cirrhosis and rarely HCC. A great deal of evidence suggests that the metabolic syndrome predicts incident cardiovascular disease (CVD), so it is possible to hypothesize that NAFLD patients might portend a greater CVD risk and that NAFLD itself might confer a CVD risk above that associated with individual metabolic syndrome risk factors. Methods: 55 T2DM patients were included in current study conducted from August 2019 to September 2021 for assessment of NAFLD using USG abdomen, NAFLD fibrosis score and FIBROSCAN. ASCVD score was used for correlation between CVD risk and NAFLD. Results: Out of 55 patients 42 (76.4%) were having fatty liver based on USG abdomen while 13 (23.4%) patients were having no fatty liver. As far as steatosis is concerned mean CAP (dB/m) was 245±50.89 out of which 24 (43.6%) were having no or minimal steatosis (S0), while 31 (56.4%) were having significant steatosis with 11 (20%), 9 (16.4%) and 11 (20%) having S1, S2 and S3 grade of steatosis respectively. 15 patients out of 55 were of F0 grade while 19 (34.5%), 9 (16.4%), 7 (12.7%) and 5 (9.1%) were of grade F1, F2, F3 and F4 respectively. There was a positive statistically significant (p≤0.001) association of ASCVD risk score with NAFLD fibrosis s core and fibroscan: E (KPa). Conclusions: Our study found that the prevalence of NAFLD was quite higher in patients with T2DM based on both USG abdomen (76.4%) and transient elastography (steatosis-56.4% and fibrosis-65.5%) and a statistically significant association between fibrosis and ASCVD score with higher fibrosis associated with higher 10 years ASCVD score. Keywords: Non-alcoholic fatty liver disease, NAFL, Non-alcoholic steatohepatitis Department of Medicine, GSVM Medical College, Kanpur, Uttar Pradesh, India Received: 12 March 2022 Revised: 05 April 2022 Accepted: 06 April 2022 *Correspondence: Dr. Vinit Kumar, E-mail: 14vinit1994@gmail.com Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. DOI: https://dx.doi.org/10.18203/2349-3933.ijam20221093